Unlocking Precision Oncology: The Interoperability Imperative

Precision oncology is about tailoring cancer treatments using a patient’s specific genetic and molecular data. The real work, however, isn’t just in the AI models or the sequencing. It’s in the data plumbing, the massive, unglamorous challenge of moving huge, disconnected datasets smoothly and securely. If the data can’t flow from one system to another in a standardized, reliable way, then no AI model can do its job. This is a data plumbing problem before it’s a modeling problem.

The Interoperability Imperative for Oncology Data

Any oncology program is drowning in data. You have electronic health records (EHRs) with patient demographics and treatment histories, imaging studies, pathology reports, and a constant firehose of high-throughput genomic and proteomic data. The hard part is getting all those different streams to talk to each other and form a single, computable picture that a doctor can actually use for a decision right now. Without good health IT interoperability, that information stays stuck in separate silos, basically useless for any real analysis. This is where the Fast Healthcare Interoperability Resources (FHIR) standard comes in. Through FHIR AI integration, these records get a path to move, turning raw files into something a clinical system can use. It creates a common language for different health IT systems to exchange information so that a data point from a lab report means the same thing as one from an EHR. For precision oncology, this kind of standardization is everything. A single missing or misinterpreted piece of data can send a whole treatment plan in the wrong direction. You don’t have a real data system until you can move and interpret records consistently.

Vertical AI Health Platforms: A Data-First Approach

The new wave of vertical AI healthcare companies gets this data problem. They build their disease-specific AI health platforms by first engineering the data pipelines and interoperability frameworks needed to get high-quality, actionable data into their algorithms. Their work is a deep dive into one medical domain, and it always involves a ton of regulatory compliance. Take Tempus AI. It’s an oncology-focused company that exemplifies this vertical approach, integrating huge amounts of clinical and molecular data to help with precision treatment decisions. Tempus has also been busy on the regulatory front, getting multiple FDA 510(k) clearances for AI-powered cardiology products like Tempus ECG-PH for pulmonary hypertension (August 2026), Tempus ECG-MR for mitral regurgitation (September 2026), and an updated Tempus Pixel cardiac imaging platform (September 2025). Their entire business model depends on being able to pull in, standardize, and make sense of messy, heterogeneous oncology data. It’s about building the infrastructure to get that data into a doctor’s existing workflow where it can actually improve patient care. This focus on data integration and regulatory legwork is the common denominator for the leading vertical AI platforms. Tempus AI is in oncology, but you see the same pattern everywhere:

• HeartFlow: In cardiology, HeartFlow’s method for analyzing CT scans to spot coronary artery disease is built on getting and interpreting data correctly. HeartFlow got its FDA 510(k) clearance for the Next Gen HeartFlow Plaque Analysis algorithm in September 2025, which gives it even better tools to analyze and show plaque. Their algorithms take complicated imaging data and turn it into functional information, which requires a solid interoperability backbone to get the raw scans in and send actionable reports back to doctors. HeartFlow technology overview
• Hinge Health: Over in musculoskeletal care, Hinge Health’s digital therapy platform is pulling together patient-reported outcomes, sensor data from wearables, and information on exercise adherence. The medical field is different, but the core idea is the same: specialized AI needs specialized data pipelines and a real commitment to regulatory compliance to keep data private and prove the therapy works. These companies have different clinical targets, but they all start by solving the “data plumbing problem.” That vertical focus lets them build specific interoperability tools that fit the unique data types and workflows of their field, instead of trying a generic approach that fits nothing well.
  

  Regulatory Compliance and the Trust Equation

  When an oncology program director is evaluating a precision medicine data partner, the vendor’s commitment to regulatory compliance and data governance is just as important as their algorithmic claims. You can spot the serious vertical AI firms by their significant investment here, because they know that healthcare data is governed by strict legal and ethical rules. Certifications like HIPAA, HITRUST, and SOC 2 are proof of a real, operational commitment to data security and privacy. HHS HIPAA compliance guidelines For a precision oncology program, handing patient data over to a third-party platform means you need absolute confidence that they can protect it and follow every regulation. This is the clear line between a research-grade dataset and a clinical input. A research dataset can get away with some inconsistencies or looser security, but a clinical input that directly affects a patient’s treatment has to meet the absolute highest standards for accuracy, reliability, and security. The sheer effort needed to get regulatory clearances like a 510(k) or a De Novo classification for AI as a Software as a Medical Device (SaMD) also tells you a lot about a vendor’s maturity. While that process isn’t just about interoperability, getting that clearance shows a company can handle complex healthcare systems and build tools that are verifiably safe and effective, which all comes back to having well-controlled and managed data.

  Evaluating Partners: What to Check Without a Vendor Conversation

  As an oncology program director, you can start evaluating potential precision medicine data partners by looking at their public posture on interoperability and regulation, long before you ever get on a call with them. 1. Check for a FHIR-first mindset: Do their public materials and technical documents mention FHIR AI integration or other standard protocols by name? A company that’s vocal about using FHIR is a company that’s thinking seriously about data exchange.

1. Look for regulatory bona fides: Do they clearly list certifications for HIPAA, HITRUST, or SOC 2 Type II? These are the table stakes for handling any sensitive patient data.
2. Assess their vertical specialization: Does the vendor seem to know the difference between genomic data, pathology reports, and clinical trial data in oncology? A general AI company might not grasp the specific data workflows and nuances that are routine in cancer care.
3. Review their published work on data quality: You can often get a sense of a company’s data governance and quality standards by reading their white papers, academic publications, or conference presentations. What are they proud of? PubMed articles on data quality in precision medicine Making precision oncology work means turning a mess of complex data into clear clinical intelligence. That transformation is an achievement of interoperability, not just of algorithms. By choosing partners who prove they’ve solved the data plumbing problem through deep specialization and serious regulatory work, oncology programs can build a real foundation for truly personalized cancer care.